Reduced injection risk behavior with co-located hepatitis C treatment at a syringe service program: The accessible care model

被引:0
|
作者
Lee, Claire So Jeong [1 ]
Mateu-Gelabert, Pedro [2 ]
Melendez, Yesenia Aponte [2 ]
Fong, Chunki [2 ]
Kapadia, Shashi N. [3 ]
Smith, Melinda [3 ]
Marks, Kristen M. [3 ]
Eckhardt, Benjamin [4 ]
机构
[1] Univ Toronto, Dept Med, Toronto, ON, Canada
[2] CUNY, Grad Sch Publ Hlth & Hlth Policy, New York, NY USA
[3] Weill Cornell Med, New York, NY USA
[4] NYU, Sch Med, New York, NY USA
来源
PLOS ONE | 2024年 / 19卷 / 08期
关键词
OPIOID USE DISORDER; VIRUS-INFECTION; DRUG-USERS; PEOPLE; STRATEGIES; RETENTION; BURDEN; HCV; INTERVENTION; MEDICATIONS;
D O I
10.1371/journal.pone.0308102
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The main mode of transmission of Hepatitis C in North America is through injection drug use. Availability of accessible care for people who inject drugs is crucial for achieving hepatitis C elimination.Objective The objective of this analysis is to compare the changes in injection drug use frequency and high-risk injection behaviors in participants who were randomized to accessible hepatitis c care versus usual hepatitis c care.Methods Participants who were hepatitis C virus RNA positive and had injected drugs in the last 90 days were enrolled and randomized 1:1 to an on-site, low threshold accessible care arm or a standard, referral-based usual care arm. Participants attended follow-up appointments at 3, 6, 9, and 12 months during which they answered questions regarding injection drug use frequency, behaviors, and treatment for opioid use disorder.Primary outcomes The primary outcomes of this secondary analysis are the changes in the frequency of injection drug use, high-risk injection behaviors, and receiving medication for opioid use disorder in the last 30 days.Results A total of 165 participants were enrolled in the study, with 82 participants in the accessible care arm and 83 participants in the usual care arm. Participants in the accessible care arm were found to have a statistically significant higher likelihood of reporting a lower range of injection days (accessible care-by-time effect OR = 0.78, 95% CI = 0.62-0.98) and injection events (accessible care-by-time effect OR = 0.70, 95% CI = 0.56-0.88) in the last 30 days at a follow-up interview relative to those in the usual care arm. There were no statistically significant differences in the rates of decrease in receptive sharing of injection equipment or in the percentage of participants receiving treatment for opioid use disorders in the two arms.Conclusion Hepatitis C treatment through an accessible care model resulted in statistically higher rates of decrease in injection drug use frequency in people who inject drugs.
引用
收藏
页数:16
相关论文
共 12 条
  • [1] Postpartum Hepatitis C Linkage to Care Program in a Co-located Substance Use Disorders Treatment Model
    Cheedalla, Aneesha
    Hinely, Katherine
    Roby, Lauren
    Hall, O. Trent
    Malvestutto, Carlos
    Rood, Kara M.
    MATERNAL AND CHILD HEALTH JOURNAL, 2023, 27 (SUPPL 1) : 87 - 93
  • [2] Postpartum Hepatitis C Linkage to Care Program in a Co-located Substance Use Disorders Treatment Model
    Aneesha Cheedalla
    Katherine Hinely
    Lauren Roby
    O. Trent Hall
    Carlos Malvestutto
    Kara M. Rood
    Maternal and Child Health Journal, 2023, 27 : 87 - 93
  • [3] Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
    Severe, Brooke
    Tetrault, Jeanette M.
    Madden, Lynn
    Heimer, Robert
    DRUG AND ALCOHOL DEPENDENCE, 2020, 213
  • [4] Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program
    Winetsky, Daniel
    Burack, Daniel
    Antoniou, Pantelis
    Garcia, Bill
    Gordon, Peter
    Scherer, Matthew
    JOURNAL OF INFECTIOUS DISEASES, 2020, 222 : S392 - S400
  • [5] Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings
    Ngo, Belle, V
    James, Jocelyn R.
    Blalock, Kendra L.
    Jackson, Sara L.
    Chew, Lisa D.
    Tsui, Judith, I
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 131
  • [6] Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia
    Treloar, Carla
    Rance, Jake
    Grebely, Jason
    Dore, Gregory J.
    DRUG AND ALCOHOL DEPENDENCE, 2013, 133 (02) : 529 - 534
  • [7] Treatment of Women With Hepatitis C Diagnosed in Pregnancy: a Co-Located Treatment Approach
    Kushner, Tatyana
    Lange, Marcia
    Sperling, Rhoda
    Dieterich, Douglas
    GASTROENTEROLOGY, 2022, 163 (05) : 1454 - +
  • [8] Barriers to Hepatitis C Treatment and Interest in Telemedicine-Based Care Among Clients of a Syringe Access Program
    Loy, Dorothy E.
    Kamis, Kevin
    Kanatser, Ruth
    Rowan, Sarah E.
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (03):
  • [9] Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus Management in Opioid Use Disorder Patients on Methadone
    Talal, Andrew H.
    Andrews, Phyllis
    Mcleod, Anthony
    Chen, Yang
    Sylvester, Clewert
    Markatou, Marianthi
    Brown, Lawrence S.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (02) : 323 - 331
  • [10] How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting
    Treloar, Carla
    Rance, Jake
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2014, 25 (05) : 865 - 870